Abstract: Recent phase I/II adeno-associated viral vector-mediated gene therapy clinical trials have reported remarkable success in ameliorating disease phenotype in hemophilia A and B. These trials, which highlight the challenges overcome through decades of preclinical and first in human clinical studies, have generated considerable excitement for patients and caregivers alike. Optimization of vector and transgene expression has significantly improved the ability to achieve therapeutic factor levels in these subjects. Long-term follow-up studies will guide standardization of the approach with respect to the combination of serotype, promoter, dose, and manufacturing processes and inform safety for inclusion of young patients. Certain limitations preclude universal applicability of gene therapy, including transient liver transaminase elevations due to the immune responses to vector capsids or as yet undefined mechanisms, underlying liver disease from iatrogenic viral hepatitis, and neutralizing antibodies to clotting factors. Integrating vectors show promising preclinical results, but manufacturing and safety concerns still remain. The prospect of gene editing for correction of the underlying mutation is on the horizon with considerable potential. Herein, we review the advances and limitations that have resulted in these recent successful clinical trials and outline avenues that will allow for broader applicability of gene therapy.
Introduction
Hemophilia is an X-linked bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) or factor IX (FIX) function due to mutations in the F8 or F9 gene, respectively. 1 FVIII deficiency, or hemophilia A (HA), accounts for 80% of cases and affects 1:5000 male births while FIX deficiency, or hemophilia B (HB), affects 1:30,000 male births worldwide. 1 In both disorders, bleeding severity correlates with residual factor activity wherein patients who have less than 1% activity (severe disease) present with frequent, spontaneous hemorrhages in joints (hemarthrosis), soft tissue, and muscles. Bleeding may also occur into closed spaces (e.g. intracranial or retroperitoneal), which can be life threatening. Patients with moderate disease (1-5% activity) only rarely have spontaneous bleeds, and those with mild disease (5-30% activity) generally only present with trauma-induced or postsurgical bleeding. 1 The current standard of care for patients with severe disease is initiation, in childhood, of lifelong prophylaxis with exogenous factor replacement to limit spontaneous bleeds in an effort to curtail morbidity and mortality. 2 However, in the United States, only around 60% of young adults and adults report adherence to prophylaxis due to its inherent complexity, 3 resulting in unacceptable rates of bleeding and long-term joint complications. Further, challenges of intravenous factor administration in young patients and lack of access to factor concentrates in developing countries pose additional barriers to optimal prophylaxis administration.
Cloning of the F8 4 and F9 5 genes not only allowed for the generation of recombinant clotting factors 6, 7 for therapy but also instigated gene therapy efforts to, at first, ameliorate phenotype or give simplified prophylaxis and, more recently, potentially cure disease. Hemophilia is an optimal target for gene therapy due to the monogenic nature of inheritance and the observation that even minimal increases in clotting factor activity can significantly improve quality of life. 1 Lessons from early gene therapy trials 8, 9 have been integrated into recent successful early phase clinical trials for both HA and HB. [10] [11] [12] [13] [14] Although gene therapy targeting the liver has come a long way, certain limitations preclude its ability to become a definitive cure for all patients; overcoming these will be of utmost importance in the coming years. 15 Here, we review the advances that have resulted in recent successful phase I/II clinical trials and outline avenues that will allow for broader applicability of gene therapy. In particular, we focus on the needs of patients with pre-existing neutralizing alloantibodies to the vector or the clotting factors (clinically termed inhibitors), those with liver disease, and pediatric patients.
Recent successes in gene therapy for hemophilia
Decades of preclinical and clinical work have resulted in the current successful phase I/II gene therapy trials for hemophilia. All published and currently open studies use adeno-associated viral (AAV) vectors. [8] [9] [10] [11] [12] [13] [14] AAV is a replication defective member of the parvovirus family and is nonpathogenic in humans. 15 The vector genome is manipulated to replace the AAV coding sequences with the transgene of interest under the control of a tissue-specific promoter, such as in liver gene therapy, to yield a recombinant AAV (rAAV) vector ( Figure 1 ). rAAV is a nonintegrating vector and the vector genome is maintained episomally in transduced cells. The size of the AAV genome (~4.7 kb) limits the size of the packaged transgene, 15 such that the F9 cDNA at 1.6 kb 5 was easier to incorporate than the 7 kb F8 cDNA. 16 Even after removal of the F8 B domain (~2.6 kb), which is not required for coagulation function, 16 incorporation of F8 cDNA has been accomplished slowly by a combination of distinct strategies. 17, 18 Thus, early studies focused on HB given the smaller size of the F9 gene, despite its lower prevalence.
In an early AAV clinical study with percutaneous injection of AAV2-FIX into skeletal muscle, the levels of neutralizing antibodies (NAbs) to AAV2 did not preclude local gene transfer or FIX transgene expression. 9 Thus, in the subsequent first liver-directed gene therapy trial for HB, the presence of NAbs to AAV was not listed in the exclusion criteria. 8 This trial demonstrated the ability to achieve therapeutic FIX levels in the highest dose cohort [2 × 10 12 vector genomes/kg (vg/kg)] using AAV2 and a wild-type FIX transgene (FIX-WT). 8 The low and intermediate dose cohorts (8 × 10 10 -4 × 10 11 vg/kg) were designed as subtherapeutic doses to assess safety. The first patient in the high-dose cohort achieved a FIX level of around 12% but then developed a cellular immune response against the AAV capsid, as noted by a transient increase in liver enzymes and decrease in transgene expression. 8 In contrast to the intramuscular trial, the second patient's transduction efficiency was hindered by pre-existing NAbs to the AAV capsid. 8 Pre-existing NAbs can be present in 30-70% of the general population for a given AAV serotype. 19 Subsequent liverdirected trials, therefore, excluded patients with pre-existing NAbs to the trial AAV serotype and planned for immunosuppression with steroids if liver enzymes increased or factor expression decreased in order to limit the capsid-triggered cellular immune response. [10] [11] [12] [13] [14] 20 All studies to date have used an AAV serotype with liver tropism utilizing a codon optimized transgene under the control of a liver-specific promoter. 8, [10] [11] [12] [13] [14] 20 Differences in AAV serotype, CpG content of the transgene, vector inverted tandem repeats (ITRs), presence of empty capsids as byproducts, and manufacturing cell line comprise the major differences between products 21 (Figure 1 , Tables 1 and  2 ). Some trials are utilizing hyperactive transgenes in an effort to decrease vector dose, which has been successful. 10 Table 1 provides a summary of recently completed and open AAV-based trials for HB. The initial AAV2-FIX-WT trial by Manno and colleagues infused patients via the hepatic artery to enhance hepatocyte transduction. 8 AAV8, compared with AAV2, has higher liver-specific tropism allowing for peripheral infusion of the vector. 13,14 Building on the lessons from the AAV2 trial, the next HB study sponsored by St Jude Children's Research Hospital (SJCRH) and University College of London (UCL) infused AAV8-FIX-WT in 10 subjects at doses between 2 × 10 11 and 2 × 10 12 vg/kg and excluded patients with anti-AAV8 NAbs. 13, 14 This study demonstrated sustained FIX activity of 3-5%, in a dose-dependent manner, with no long-term safety issues identified at 3 years, with ongoing follow up. 13, 14 However, four of six subjects in the high-dose cohort had elevated liver transaminases concomitant with a positive T-cell enzyme-linked immunospot (ELISPOT) assay against the AAV capsid, signifying a capsid-triggered cellular immune response [ Figure 2 (a)]. Gaining from the experience of the earlier AAV2 study, 8 this study was the first to identify that prompt initiation (<48 h) of steroids in the presence of increased liver enzymes or drop in transgene expression levels prevented further loss of FIX activity. 13, 14 In the follow-up study with an additional four patients infused in the high-dose cohort, the annualized bleed rate (ABR) dropped from a median of 16.5 to 1 (94%) and overall ABR decreased from 15.5 to 1.5 (90%) in a vector dose-dependent manner. 13, 14 The observation that there is vector dose dependency on the rate and presence of immune response to the vector capsid prompted the development of strategies to allow lower therapeutic vector doses. The identification of a naturally occurring hyperactive FIX variant (FIX-Padua), which yields approximately eightfold increased specific activity, 25 afforded the opportunity to achieve therapeutic FIX levels with a lower vector dose. Our laboratory reported success with this strategy in inhibitor-prone HB dogs treated with AAV8 carrying canine (c) FIX-Padua at 1-3 × 10 12 vg/kg with therapeutic FIX levels of 25-200%. 26 There was no clinical or laboratory evidence of thrombosis and no antibody to the transgene after recombinant cFIX-WT infusion. In these dogs, Figure 1 . Overview of adeno-associated virus (AAV) mediated liver-directed gene therapy for hemophilia. The wildtype AAV genome consists of two inverted tandem repeat (ITR) regions flanking the rep (replication) and cap (capsid) genes. These genes are replaced by a tissue-specific promoter with enhancer, intron, and transgene of interest in the recombinant (r)AAV vector genome, which is packaged into capsids and injected into subjects via a peripheral venous infusion. Once infused, rAAV vector can be neutralized by pre-existing antibodies in a serotype-specific manner or transduce hepatocytes where the capsid is degraded and the genetic material maintained as an episome in the nucleus to produce the transgene product. Capsid peptides can be presented on the surface of hepatocytes to CD8+ T cells, thought to lead to a cellular immune response coinciding with loss of transgene and rise in liver transaminases in some clinical trials. Modifications in the transgene, serotype, infusion of empty capsids, and production process may all affect efficacy. Options to bypass the pre-existing humoral response or liver disease are listed. Additional hurdles to general application of liver-directed AAV gene therapy include inhibitors to factors VIII and IX as well as infusion in young patients. FVIII, factor VIII; FIX, factor IX; CpG, cytosine-guanine residues. cFIX-Padua specific activity was similar to that of FIX-Padua in the original family. 26 Subsequently, a clinical study by Shire (Dublin, Ireland) utilizing AAV8-FIX-Padua at doses of 2 × 10 11 to 3 × 10 12 vg/kg demonstrated longterm expression of FIX at 20% in a single subject infused with 1 × 10 12 vg/kg without development of inhibitors to the transgene. 22 However, in the mid-and high-dose cohorts, after near normal FIX activity, immunosuppression with prednisone did not prevent loss of transgene expression caused by the cellular immune response to the capsid. 22, 27 In the study sponsored by Spark Therapeutics, (Philadelphia, PA, USA) a novel AAV serotype (Spark100) with FIX-Padua was infused in 10 subjects at a fixed dose of 5 × 10 11 vg/kg and resulted in sustained FIX activity of around 30% with lower rates of immune response to the vector capsid. 10 Only two of 10 subjects required steroids compared with four of six in the SJCRH/UCL trial. Notably, these patients retained FIX levels within the mild deficiency to normal range even after prednisone was discontinued (30-80%). All patients have stopped prophylaxis with a concurrent decrease in ABR from 11.1 to 0.4 (96%) and there has been no evidence of inhibitor formation to FIX-Padua. 10 The planned phase III trial utilizing this vector will be sponsored by Pfizer (New York, NY, USA). 28 The trials mentioned above used AAV vectors generated in mammalian cells using triple transfection of plasmid DNA for vector production. 8, 10, 13, 14, 20 The uniQure-sponsored HB trial utilized AAV5-FIX-WT generated in an insect cell line using a baculovirus production system at doses of 5 × 10 12 and 2 × 10 13 vg/kg, with five subjects in each cohort. 11 Results show mean steady-state FIX activity of 3-12% with a decrease in spontaneous ABR from 9.8 to 4.6 (53%) in the low-dose cohort and from 3 to 0.9 (70%) in the high-dose cohort. 11 However, there was not a clear linear dose response to the vector, as despite a fourfold higher vector dose there was only 1.6-fold higher FIX activity. 11 Furthermore, although three of ten subjects had an increase in alanine aminotransferase (ALT) and received steroids, this was neither associated with anti-capsid cellular immune response nor did it have an effect on FIX activity 11 [ In the high-dose cohort (n = 7), the first treated subject had an increase in ALT (1.5 fold baseline but below the upper limit of normal) between weeks 4 and 7, prompting the use of steroids for a presumed capsid-triggered immune response. All subsequent patients in the high-dose cohort were treated prophylactically with steroids. As in the AAV5-FIX uniQure trial, 11 in the Biomarin trial there was no clear evidence of a connection between increased ALT, anti-capsid T-cell response, steroid use, and FVIII activity [ Table 2 , Figure 2 (b)]. In four of the seven patients on high-dose treatment, steroid therapy did not halt ALT elevation. Normalization of ALT with respect to steroid discontinuation varied widely, with some patients having increases even after steroids were stopped. The steroid dose was titrated down as per the protocol in all patients. Prior studies have shown correlation between ALT and capsid-triggered immune response 8,10,13,14 but no capsid-directed T-cell response was seen in these HA subjects, raising the question of whether the ALT elevation seen here is not an immune response but rather potential hepatocyte toxicity or other unknown effects. 12 The exact mechanism behind this outcome is not completely understood and remains under investigation but raises the question of whether the insect-line, baculovirus system manufacturing process, or the AAV5 immune response may differ from other rAAV vectors produced in mammalian lines using plasmid DNA. Over a 12-month observation period, ABR decreased 94% from 16 to 1 and the reported FVIII activity ranged between 19% and 164% without a linear dose response (threefold higher dose between cohorts with 10-to 80-fold increased FVIII activity). 12 The safety of chronic supraphysiologic FVIII activity is unknown and may carry a risk of thrombosis; 29,30 furthermore, these levels are unnecessary for phenotypic improvement. Long-term follow-up data from these subjects may guide the efficacy and further understanding of the mechanism of this strategy. A phase III trial is planned using vector doses from 4 × 10 13 to 6 × 10 13 vg/kg. 12
AAV liver-directed HB clinical trials
Spark Therapeutics has also reported early results from its phase I/II clinical trial using a novel AAV serotype (Spark200/LK03 31 ) with BDD-FVIII at doses of 5 × 10 11 (low dose), 1 × 10 12 (intermediate dose), and 2 × 10 12 vg/kg (high dose). The two patients each treated at the low and intermediate dose had steady-state FVIII levels of 10-13% and 9-13%, respectively. 24 The first intermediate dose subject (1 × 10 12 vg/kg) had increased ALT and was started on immunosuppression with stable FVIII activity thereafter, and the second subject was treated with steroids empirically. Data from the high-dose (2 × 10 12 vg/ kg) subjects have not yet been released. As in the HB trials, there is wide variation in vector dose between these HA trials (~60-fold higher vector dose for Biomarin compared with Spark HA trial), and whether one strategy may be more successful remains to be determined. There are also concerns about manufacturing feasibility, and the short duration of follow up of these recent trials precludes definite safety assessment at this point.
Future and challenges of gene therapy
The variety of AAV serotypes, the wide range of therapeutic vector doses, and differing manufacturing processes make a comparison of these products very difficult. However, the common threads amongst these trials are the following exclusion criteria: patients under 18 years of age; patients with less than 30-50 exposure days to FVIII/FIX concentrates; underlying liver disease or active viral hepatitis B or C infections (HBV/ HCV); presence of NAbs to AAV serotype higher than a cutoff; and current or prior history of inhibitors to FVIII or FIX. Despite promising results, due to the limits imposed by these exclusion criteria, gene therapy is not yet at the point of being universally applicable to all persons with hemophilia. Notably, in the United States, like many other countries, the high prevalence of HCV in patients with hemophilia over the age of 35 (in 2018) means that over 35% of adult patients who could benefit from gene therapy will be ineligible for these liver-directed approaches. 3 What impact, if any, the ability to cure HCV with new antivirals will have remains to be seen. Finally, up to 30% of patients with severe HA and 5% of patients with severe HB develop inhibitors to the infused protein, 39 which decrease or nullify achievement of hemostasis with replacement protein. Currently, the only known curative strategy for inhibitors is infusion of frequent, high doses of factor concentrates over a period of months to years termed immune tolerance induction (ITI), which is moderately (~60%) successful in patients with favorable risk characteristics. 40 The goal of ITI is to allow the use of FVIII/FIX protein for replacement therapy as they more effectively achieve hemostasis than alternative bypassing agents (BPAs), such as activated prothrombin complex concentrates (aPCCs) or recombinant factor VIIa (rFVIIa), 41 which circumvent the need for FVIII and thereby provide alternate pathways for generation of thrombin. While ITI is more cost effective than life-long BPA therapy for hemostasis, it comes at great economic burden (~$1 million for a 20 kg patient) and is demanding, as evidenced by around 20% of patients withdrawing from participation in the International ITI (I-ITI) study. 40 40 This study identified the characteristics of patients who were more likely to achieve tolerance as follows: BU less than 10 at start of ITI; historical peak BU less than 200; young age; and short time between diagnosis and ITI start. 40 While around 60% of patients with these favorable risk factors will achieve tolerance with ITI, there are not good options for those with refractory or relapsed inhibitors. 50 Furthermore, the time to reach BU less than 10 ranged from 3 to 8 months in I-ITI, and a subset of patients were unable to be randomized in the trial due to persistent BU greater than 10. 40 Prior attempts at immunosuppressive regimens alone or coupled with ITI have had mixed and modest success at inhibitor eradication. 51, 52 Alternative strategies that simplify ITI are clinically necessary and could provide tremendous benefits to inhibitor patients. Indeed, the preclinical data below support the hypothesis that liver-directed gene therapy can provide the dual benefits of both eradicating inhibitors to the clotting factor and providing simplified prophylaxis thereafter. 53 While several animal models of hemophilia have been characterized, 54 the canine model 55 is unique for several reasons: dogs naturally have hemophilia resulting from a spectrum of genetic mutations similar to humans; the disease phenotype is similar to humans; compared with mice, the colonies are outbred and of various genetic (and thereby immune) backgrounds; and characterization of cFVIII 56 and cFIX 57 cDNA affords the ability to produce recombinant cFVIII/cFIX protein for species-specific immunologic studies. 53 The canine HA and HB models differ in their backgrounds, genetic mutations, and predisposition to antifactor immune responses (Table 3) . While the HA dogs from Queens University (QU) 58 and University of North Carolina (UNC-CH) 59 both have mutations similar to the human F8 intron 22 inversion, the QU HA dogs were initially more inhibitor prone after exposure to cFVIII. Subsequent introduction of an outside male breeder to the UNC-CH HA colony has created a subset of inhibitor-prone HA dogs there as well. 46 Murine hemophilia models, in contrast, are generally limited to two strains with very similar mutations, and immune studies are complicated by infusion of human xenoprotein. 60 Nonetheless, in both canine and murine models, mounting preclinical data demonstrate that consistent endogenous expression of FVIII/FIX after liver-directed gene therapy can result in transgene-specific immune tolerance and eradicate pre-existing inhibitors. 26, 46, [61] [62] [63] [64] [65] [66] In contrast, collective data from nonhuman primates (NHPs) in AAV liver gene therapy for HB or HA resulted in inhibitor formation due to the use of a human transgene and precluded the consideration of transgene-specific ITI by gene therapy. 17 In the canine and murine liver-directed gene therapy studies, it was demonstrated that tolerance occurs through induction of a regulatory T-cell (Treg) response and other mechanisms. 46, 61, 62 Further evidence supporting the role of Tregs comes from a NHP study where the use of an anti-CD25 antibody, which depletes both T effector and Tregs, during the early phase of AAV2 liver-directed FIX expression resulted in inhibitor formation. 67 The exact mechanism behind ITI by frequent exposure of FVIII/FIX protein concentrates is not completely understood, but the rationale is that prolonged and consistent antigen exposure would tilt the balance towards tolerance. The advantage of gene therapy for ITI is the opportunity to provide this continuous antigen endogenously with a single infusion. 68 Our laboratory investigated whether gene therapy could eradicate pre-existing inhibitors and thereafter allow for simplified prophylaxis with endogenous FVIII/ FIX production. Within the UNC-CH HA inhibitor prone model, three dogs with historically high titers were able to eradicate their inhibitors 4-5 weeks after liver-directed AAV gene therapy with progressively increasing FVIII levels and improvement in the bleeding phenotype. In addition, they demonstrated normal pharmacokinetics to infused cFVIII recombinant protein thereafter, 46 in line with criteria for successful tolerance from I-ITI. A QU-HA dog who had developed inhibitors after prior exposure to human FVIII, which can cross react with cFVIII, given the same therapy had an anamnestic response that peaked at 216 BU but achieved tolerance by 18 months post infusion. 46 In fact, in ITI an anamnestic response greater than 200 BU was negatively correlated with tolerance induction. 69 Although this dog took longer to achieve FVIII tolerance, consistent endogenous antigen exposure via gene therapy was ultimately successful at eradicating the pre-existing inhibitor to both human and canine FVIII (unpublished observation, V.R.A. and Finn and colleagues 46 ). In the canine HA inhibitor model, we have also noted an increase in Tregs with liver-directed gene therapy that precedes antibody eradication, 46,68 whereas in dogs 75, 76 which is the main goal of ITI. Given the inability to predict exact prohemostatic effects from these drugs, they may pose thrombotic risks 21 when combined with other clotting factors for bleeding, as evidenced by thrombosis (including thrombotic microangiopathy) in five patients in the emicizumab trial 75 when treated concurrently with aPCC for more than 24 h due to bleeding and one patient in the fitusiran trial 79 whose cavernous sinus thrombosis was initially thought to be a subarachnoid hemorrhage and received several doses of FVIII. Thus, likely the best therapeutic choice for a clotting factor deficiency is replacement of the clotting factor 41 as the ideal replacement or BPA therapy, and dosage in the setting of these newer agents remain unclear. The tremendous physical, financial, and psychosocial morbidity [80] [81] [82] [83] for inhibitor patients can be significantly ameliorated if gene therapy is able to eradicate their inhibitors with a one-time infusion. Moreover, the presence of inhibitor in adolescent boys is also associated with delayed growth and maturation, 84 thus it is imperative to eradicate inhibitors rather than just using BPAs. As clinical gene therapy trials move into phase III studies, a powerful and meaningful next step would be to include patients with inhibitors as this can provide the dual benefits of eradicating the inhibitor and improving the disease phenotype with one infusion.
Patients with underlying liver disease
Prior to the advent of recombinant factors, patients with hemophilia were infused with pooled cryoprecipitate or plasma-derived factors. 1 The first evidence of liver injury in people with hemophilia treated with these products emerged in the 1970s with asymptomatic elevated transaminases documented in 45% of patients, 85 which persisted for several years and was found in the 1980s to cause progressive cirrhosis. Although HBV was known to play a role, the identification of HCV as a contributor to this phenomenon did not occur until 1987. 86 Another safety issue is the concern for both acute and long-term hepatic genotoxicity from AAV vectors themselves. Studies have suggested a protective role of WT AAV in cancer. [89] [90] [91] Indeed, athymic nude mice injected with a colon cancer cell line treated with WT AAV2 had decreased tumor growth due to selective apoptosis induced by AAV in cells that lack activity of the tumor suppressor p53. 89 Preclinical studies have assessed the risk of genotoxicity from hepatocyte transduction with AAV vectors. 92 113 and regional isolated AAV delivery to limit systemic exposure. 38 Unfortunately, all of these strategies are fraught with complications that make them suboptimal. Infusion of empty capsids allows for the adsorption of some of the circulating antibodies to allow transduction with transgeneencoded vector. 37 However, this strategy may be limited in those with high NAb titers and may increase the cellular immune response against the capsid as the total dose of vector would also need to be increased. Immunosuppression has been modestly effective at dampening but not eliminating the humoral response to AAV. 35 Further, B-cell depletion comes with associated lymphopenia and risk of infections. Plasmapheresis is a relatively safe and effective strategy for low-titer inhibitors (⩽1:20); however, despite five sessions plasmapheresis was not able to decrease NAb titers below 1:5 for patients with initially high titers (>1:20). 36 Patients with high-titer antibodies are more acutely in need of successful strategies and the limited efficacy of plasmapheresis is unlikely to be beneficial for this population. Localized liver perfusion 38 or isolated limb perfusion 108, 114 with skeletal muscle delivery of vector, therefore, may be a viable option for patients with high NAb titers to liver tropic AAV serotypes. Likely, a combinatorial approach of these strategies will be needed to overcome preexisting NAbs.
Lentiviral gene therapy
While AAV has emerged as the most successful vector for in vivo hemophilia gene therapy to date, there has been considerable effort in developing integrating vectors, such as retroviruses. 115 A potential advantage of this system is the ability to propagate the integrated transgene into progeny of the transduced cells, thereby avoiding potential dilution from organ or blood volume growth and allowing long-term therapy in young patients. Retroviruses are single-stranded RNA viruses containing a reverse transcriptase to allow for viral DNA production, which can then integrate into the host genome via an integrase. Initial studies demonstrated the ability to achieve therapeutic FIX (12-36%) and FVIII (116-139%) levels in neonatal hemophilic dogs treated with γ-retrovirus vector at 0.8-1.3 × 10 10 transduction units (TU)/kg and 0.7-0.9 × 10 10 TU/kg, respectively. 65, 116 A phase I clinical trial sponsored by Chiron (San Diego, CA, USA) utilizing Moloney murine leukemia virus (MoMLV) carrying BDD-FVIII at doses of 2.8 × 10 7 to 8.8 × 10 8 TU/kg in patients with severe HA was shown to be safe and well tolerated. 117 However, there was a question of germline transmission of retrovirus via semen and FVIII activity was only transiently measured after infusion with no clear dose response. Furthermore, a clinical trial also using a retroviral vector in severe combined immunodeficiency (SCID) was complicated by leukemogenesis in four patients due to insertional mutagenesis, 118, 119 which raised significant safety concerns.
More recently, studies have focused on lentiviruses, which are members of the retrovirus family but are different from simple MoMLV in that they are able to infect nondividing cells. 120 Of note, the oncogenesis seen in retroviral-mediated gene therapy for SCID defined above has not been seen in lentivirus-mediated gene therapy trials to date. 121 Lentiviral vectors are easily capable of carrying the F8 cDNA and have decreased likelihood of preexisting NAbs in the population. Lentiviral transduction can occur either ex vivo with infusion of transduced autologous hematopoietic stem cells (HSCs) from the recipient or in vivo via intravenous infusion of vector targeting the liver. The ex vivo approach in HSCs can either be lineage restricted 122 or not. 123 In HA mice, transplantation of lentivirus-transduced HSCs with a human-porcine hybrid BDD-FVIII demonstrated therapeutic levels of 1-10%, 123, 124 even in mice with pre-existing inhibitors. Delivery of platelet FVIII via transplantation of HSCs in a similar manner did result in disease amelioration in HA dogs, 122 but further studies are needed to understand if this is tolerogenic. Ex vivo HSC lentivirus gene therapy is complicated by the need for conditioning regimens, bone marrow engraftment, or invasive procedures, which are likely to be significant hindrances for the subjects. Further large animal model studies are needed to understand the efficacy and safety profile of this approach. One approach that avoids the need for conditioning is the use of transduced autologous blood outgrowth endothelial cells (BOECs). 125 Ex vivo transduced autologous BOECs in three HA dogs via omental implantation with or without transient immunosuppression did initially result in therapeutic FVIII levels; however, this was not sustained due to the development of anti-FVIII IgG antibodies. 125 Recently, in vivo intravascular delivery of lentiviral vectors carrying FVIII and FIX targeting the liver has been carried out in animal models. [126] [127] [128] The advantage of this vector-integrating system compared with AAV is the ability to allow longterm sustained transgene expression by avoiding potential transgene dilution when delivered to pediatric patients. In these studies, the lentivirus is modified through the addition of microRNA target sites to silence expression in nontarget cells. Recent studies have shown that the endogenous production of FVIII from the liver is mainly from liver sinusoidal endothelial cells rather than hepatocytes. 129, 130 Building upon this observation, Merlin and colleagues treated HA mice with 1 × 10 9 TU of lentivirus containing BDD-FVIII under the control of an endothelial promoter and demonstrated therapeutic FVIII levels of around 3-8% with no inhibitor formation. 126 Even higher levels of FVIII activity were observed with further FVIII transgene optimization. 131 Furthermore, HA mice with inhibitors to FVIII treated with the same approach were able to eradicate pre-existing inhibitors and subsequently achieve expression of therapeutic FVIII levels. In HB, lentivirus expressing FIX-Padua modified to target the liver was successful in ameliorating disease phenotype in murine and canine HB models. 127, 128 However, at doses of 5.7 × 10 8 to 2.3 × 10 9 TU/kg, FIX activity was only around 1% in the two dogs treated at the highest dose, despite use of cFIXPadua in one dog. 128 Additionally, the first two dogs developed anaphylactoid infusion reactions necessitating steroid and antihistamine use in the third dog. Encouragingly, this vector was not associated with genotoxicity in a murine model 128 followed for around 12 months. However, the risks of insertional mutagenesis and genotoxicity in hemophilia subjects with a life expectancy over 60 years remains to be answered. Finally, in vivo lentivirus delivery is also complicated by vector stability, 132 immune response by antigen presenting cells to pseudotyped vector, 120 pre-existing antibodies to vesicular stomatitis virus used to pseudotype vector, 133 and complement binding to vector which can result in infusion reactions. 128 While lentivirus may offer significant advantages in hematopoietic and other stem-cell based disorders, there are significant challenges yet to overcome.
Gene-editing approaches
Gene-editing technologies are based on harnessing the natural repair machinery of the cell to modify DNA. Following a double-stranded break induced by a nuclease, repair progresses either through nonhomologous end joining (NHEJ) or homologydirected repair (HDR). NHEJ repair results in insertions or deletions (indels) of various lengths while HDR can be used to create precise site-and sequence-specific changes from a template. [134] [135] [136] Nucleases used to induce these breaks include zinc-finger nucleases (ZFN), transcription-activator-like effector nucleases and clustered regularly interspaced short palindromic repeat (CRISPR)/ CRISPR associated protein 9 (CRISPR/Cas9). 137 Gene editing offers several advantages over AAV and integrating vectors, including precise editing, decreased insertional oncogenesis, and control under the endogenous promoter. While early animal studies utilizing ZFN and CRISPR/Cas9 did ameliorate disease phenotype in animal models, 138 
Conclusion
Recent phase I/II AAV liver-directed gene therapy trials for hemophilia have shown remarkable decreases in ABR and factor usage, and engender optimism about the ability to significantly improve quality of life for persons with hemophilia.
Lessons from early trials incorporating strategies for vector and transgene optimization and exclusion of subjects with pre-existing NAb to vector serotype have created the ability of a one-time infusion to provide simplified, lifelong prophylaxis which is a tremendous paradigm shift for patients and healthcare providers. Notably, there is convincing evidence that FIX-Padua may be the optimal transgene in HB gene therapy and there is considerable preclinical evidence that liver-directed gene therapy for ITI in HA has translational potential for a population with limited, suboptimal, and demanding therapeutic options otherwise. A one-time infusion that allows both tolerance induction and lifelong prophylaxis after inhibitor eradication with a single infusion would have immense benefits. The preclinical and clinical trial data have yielded a wealth of information regarding factors that permit success, but additional studies are needed to answer questions of optimal transgene, serotype, dose, target clotting factor activity, and manufacturing process as well as to understand the mechanistic processes underlying the immune response and rise in liver transaminases.
Currently, AAV gene therapy is limited in its general applicability due to pre-existing NAbs and pre-existent HCV or HBV infection. Long-term follow-up studies will be critical to assessing and addressing the safety concerns and therefore allow enrollment of younger patients, as further evidence of safety around risk of genotoxicity is amassed and ways to overcome NAbs for potential reinfusion are established. In the coming years, as some trials move beyond phase I/II, we anticipate the recognition of promising strategies that would yield benefits for many more patients. Further, these studies will likely help standardize aspects such as NAb titers, manufacturing process, and serotype. Finally, there are considerations of the cost of gene therapy, both to patients and payers. Arguably, the most striking benefit would be in the developing world, where routine access to clotting factors is limited, but how gene therapy is priced will affect its availability to these patients. There is a moral imperative to develop economically priced strategies to improve the burden of disease for patients in the developing world.
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